Diagnostics News and Research

RSS

WHO, Roll Back Malaria partnership launch initiative to contain artemisinin-resistant malaria

The WHO and Roll Back Malaria partnership (RBM) on Wednesday launched an initiative to "stop a form of drug-resistant malaria from spreading from Southeast Asia to Africa, where millions of lives could be at risk," Reuters reports. "It would cost about $175 million a year to contain and prevent the global spread of the artemisinin-resistant parasite which first emerged along the Thai-Cambodian border in 2007, the United Nations agency said," according to the news agency (Nebehay, 1/12).

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

Genomic research could help doctors better target oxaliplatin drug to treat colorectal cancer patients: Study

Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. and the Translational Genomics Research Institute.

13 Jan 2011

FDA's determination of equivalency validates Neogen's rapid test for Salmonella enteritidis

Neogen Corporation today announced that its rapid test for Salmonella enteritidis (SE) has been determined by the U.S. Food and Drug Administration (FDA) to be equivalent to the FDA's traditional testing method in accuracy, precision, and sensitivity for detecting SE.

13 Jan 2011

Peninsula scientists to implement Policy Research Unit for early cancer screening and diagnosis

A team of researchers from the Peninsula College of Medicine and Dentistry are part of a wider group of researchers from leading institutions that will implement a -4.7m Policy Research Unit dedicated to achieving early cancer screening and diagnosis. The funding is provided over five years by the Department of Health and will be led by Queen Mary, University of London.

13 Jan 2011

Illumina announces acquisition of Epicentre Biotechnologies

Illumina, today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications.

From Illumina, Inc. 12 Jan 2011

GE and KeyHIE expand Pennsylvania's health information exchange

GE Healthcare and Keystone Health Information Exchange, which serves central and northeast Pennsylvania communities, have announced they are expanding the region's health information exchange to augment its chronic disease management capabilities and broaden its reach to many more healthcare providers.

12 Jan 2011

Vermillion receives USPTO patent for PAD biomarker

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued patent number 7,867,719 entitled "Beta-2 microglobulin as a biomarker for peripheral artery disease" to the Company.

12 Jan 2011

Caliper launches new LabChip Dx system for clinical research laboratories

Caliper Life Sciences, today announced the launch of Caliper's new, innovative LabChip Dx system for use by clinical research laboratories developing molecular diagnostic tests.

11 Jan 2011

OraSure to introduce QuickFlu test for detection of type A and type B influenza

OraSure Technologies, announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration approved in vitro rapid qualitative test for the detection of influenza type A and type B, including H1N1 viral infections.

11 Jan 2011

Study identifies over 30 breast cancer gene targets involved in drug resistance to chemotherapy

A new study conducted by Josh LaBaer's research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

PharPoint Research joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.

10 Jan 2011

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

nContact Surgical removes 'Surgical' from company name

nContact Surgical, Inc., a cardiac ablation device manufacturer, announced today that it is changing the name under which it operates from nContact Surgical, Inc. to nContact, Inc. As the pioneer of interdisciplinary epicardial and endocardial cardiac ablation, the change represents the Company's further evolution towards closed chest approaches to treating common cardiac arrhythmias.

10 Jan 2011

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

T2 Biosystems, Inc., a company developing next-generation medical diagnostic products, today announced that it has relocated to a newly renovated 20,000 sq.ft. facility located in Lexington, MA.

10 Jan 2011

Civitas receives $20 million Series A financing

Civitas Therapeutics, Inc., a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies, announced today that it has secured a $20 million Series A financing from founding investor, Longitude Capital, along with co-lead Canaan Partners. The proceeds of the financing will be primarily used to advance Civitas' lead program for treating patients with Parkinson's disease through clinical proof-of-concept.

10 Jan 2011

Illumina announces next generation of iSelect custom genotyping products

Illumina, Inc. today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs.

From Illumina, Inc. 10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011